596 related articles for article (PubMed ID: 16584444)
1. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
[TBL] [Abstract][Full Text] [Related]
2. TSE clearance during plasma products separation process by Gradiflow(TM).
Wang K; Johnson A; Obradovic M; Anderson G; Maclean C; Nair H
Biologicals; 2005 Jun; 33(2):87-94. PubMed ID: 15939286
[TBL] [Abstract][Full Text] [Related]
3. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter.
Sowemimo-Coker S; Kascsak R; Kim A; Andrade F; Pesci S; Kascsak R; Meeker C; Carp R; Brown P
Transfusion; 2005 Dec; 45(12):1839-44. PubMed ID: 16371036
[TBL] [Abstract][Full Text] [Related]
4. Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates.
Sowemimo-Coker SO; Pesci S; Andrade F; Kim A; Kascsak RB; Kascsak RJ; Meeker C; Carp R
Vox Sang; 2006 May; 90(4):265-75. PubMed ID: 16635068
[TBL] [Abstract][Full Text] [Related]
5. [Biology of non-conventional transmissible agents or prions].
Dormont D
Rev Neurol (Paris); 1998 Feb; 154(2):142-51. PubMed ID: 9773035
[TBL] [Abstract][Full Text] [Related]
6. Comparison of nanofiltration efficacy in reducing infectivity of centrifuged versus ultracentrifuged 263K scrapie-infected brain homogenates in "spiked" albumin solutions.
Cardone F; Simoneau S; Arzel A; Puopolo M; Berardi VA; Abdel-Haq H; Galeno R; De Pascalis A; Sbriccoli M; Graziano S; Valanzano A; Porte P; Diringer H; Brown P; Flan B; Pocchiari M
Transfusion; 2012 May; 52(5):953-62. PubMed ID: 22082124
[TBL] [Abstract][Full Text] [Related]
7. Partitioning of TSE infectivity during ethanol fractionation of human plasma.
Gregori L; Maring JA; MacAuley C; Dunston B; Rentsch M; Kempf C; Rohwer RG
Biologicals; 2004 Mar; 32(1):1-10. PubMed ID: 15026020
[TBL] [Abstract][Full Text] [Related]
8. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
9. Guanidine hydrochloride extraction and detection of prion proteins in mouse and hamster prion diseases by ELISA.
Kang SC; Li R; Wang C; Pan T; Liu T; Rubenstein R; Barnard G; Wong BS; Sy MS
J Pathol; 2003 Apr; 199(4):534-41. PubMed ID: 12635145
[TBL] [Abstract][Full Text] [Related]
10. Long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: analogies to bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in humans.
Race R; Raines A; Raymond GJ; Caughey B; Chesebro B
J Virol; 2001 Nov; 75(21):10106-12. PubMed ID: 11581378
[TBL] [Abstract][Full Text] [Related]
11. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands.
Gregori L; Lambert BC; Gurgel PV; Gheorghiu L; Edwardson P; Lathrop JT; Macauley C; Carbonell RG; Burton SJ; Hammond D; Rohwer RG
Transfusion; 2006 Jul; 46(7):1152-61. PubMed ID: 16836562
[TBL] [Abstract][Full Text] [Related]
12. Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate.
Diez JM; Caballero S; Belda FJ; Otegui M; Gajardo R; Jorquera JI
Haemophilia; 2009 Nov; 15(6):1249-57. PubMed ID: 19563480
[TBL] [Abstract][Full Text] [Related]
13. Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrP(Sc).
Gong HS; Guo Y; Tian C; Xie WL; Shi Q; Zhang J; Xu Y; Wang SB; Zhang BY; Chen C; Liu Y; Dong XP
Int J Mol Med; 2012 Sep; 30(3):569-78. PubMed ID: 22692785
[TBL] [Abstract][Full Text] [Related]
14. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
Kozak RW; Golker CF; Stadler P
Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
[TBL] [Abstract][Full Text] [Related]
15. Assessment of prion reduction filters in decreasing infectivity of ultracentrifuged 263K scrapie-infected brain homogenates in "spiked" human blood and red blood cells.
Cardone F; Sowemimo-Coker S; Abdel-Haq H; Sbriccoli M; Graziano S; Valanzano A; Berardi VA; Galeno R; Puopolo M; Pocchiari M
Transfusion; 2014 Apr; 54(4):990-5. PubMed ID: 23915063
[TBL] [Abstract][Full Text] [Related]
16. Current strategies to prevent transmission of prions by human plasma derivatives.
Burnouf T; Padilla A
Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
[TBL] [Abstract][Full Text] [Related]
17. Neuroinvasion in sheep transmissible spongiform encephalopathies: the role of the haematogenous route.
Sisó S; Jeffrey M; González L
Neuropathol Appl Neurobiol; 2009 Jun; 35(3):232-46. PubMed ID: 19473292
[TBL] [Abstract][Full Text] [Related]
18. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
[TBL] [Abstract][Full Text] [Related]
19. Clearance of prions during plasma protein manufacture.
Burdick MD; Pifat DY; Petteway SR; Cai K
Transfus Med Rev; 2006 Jan; 20(1):57-62. PubMed ID: 16373188
[TBL] [Abstract][Full Text] [Related]
20. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma.
Stenland CJ; Lee DC; Brown P; Petteway SR; Rubenstein R
Transfusion; 2002 Nov; 42(11):1497-500. PubMed ID: 12421224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
